3 Reasons SUPN is Risky and 1 Stock to Buy Instead

Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $41.99, producing a disappointing 14.7% loss - a stark contrast to the S&P 500’s 16.4% gain. This may have investors wondering how to approach the situation.